TScan Therapeutics, Inc. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
TScan announced a strategic reorganization: (1) pausing Phase 3 ALLOHA-2 enrollment for TSC-101 in heme malignancies due to insufficient capital after enrolling 7 patients on the treatment arm; (2) laying off ~75% of workforce; (3) shifting focus to in vivo-engineered TCR-T for solid tumors (PRAME and MAGE-A4 candidates entering IND-enabling studies with Phase 1 planned Q4 2027); (4) pursuing strategic partnerships for heme and autoimmune programs. The restructuring is expected to save $55M through end of 2027 and extend cash runway to Q4 2027. Updated Phase 1 ALLOHA data showed 100% (13/13) patients in Cohort C achieved complete donor chimerism with commercial-ready manufacturing.
Why this rating
Major pivot and near-total workforce reduction materially alter trajectory. ~$55M cost-cut relative to $56.9M market cap is existential restructuring. Phase 3 halt is significant setback, but strong Phase 1 ALLOHA data and solid-tumor pivot offer potential upside if executed. Funding extends only to Q4 2027; partnership-dependent.
Tradability signal
SHORT
conviction 39/100 · expected -0.74% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (16 in this cell) moved +1.90% in the called direction over 4 hrs; shrunk for sample size that's a +0.74% edge. Price is down 5.4% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 5% against entry — default width (volatility unmeasured), fixed, not trailing (trails test terribly on these names) — time exit 4 hrs.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.70 ▲ 5.67% | at our read · unknown $0.67 | +10 min · unknown $0.67 ▲ 0.00% | +30 min · unknown $0.67 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved -5.37% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.